Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06245564
Other study ID # N-20230046
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 17, 2024
Est. completion date December 31, 2025

Study information

Verified date June 2024
Source Aalborg University
Contact Silvia Lo Vecchio
Phone +4521397785
Email slv@hst.aau.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic itch affects approximately a fifth of the global population and is associated with substantial negative consequences for the affected individuals. Furthermore, there is a lack of efficient treat-ment options for chronic itch. Topical ketamine cream has been used successfully to relieve various forms of pain, and we hypothesize that topical ketamine relieves itch through a mechanism of action comparable to that in pain relief. The aim of this project is to evaluate the effects of ketamine both alone and in combination with amitriptyline on histaminergic and non-histaminergic itch induced by histamine and cowhage, respectively.


Description:

The main action of ketamine, 2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone, is to antagonize the glutamate N-methyl-D-aspartate (NMDA) receptors. In the clinical setting, topical ketamine cream has been used successfully to relieve various pathogenic forms of pain. In addition to its pain-relieving effects, the cream was also reported to have itch-relieving properties in a very limited study. However, its efficacy on itch has not been established, and the mechanism of action remains uncertain. Ketamine cream is used not only by itself, but also in conjunction with other analgesics. One of these is amitriptyline, which may enhance the analgesic effects of ketamine. The aim of this human experimental study is to use the well-characterized anesthetic Ketamine, both alone and in combination with amitriptyline, as a tool to modulate different histaminergic and non-histaminergic itch modalities evoked by histamine and cowhage.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date December 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Healthy men and women - 18-60 years - Speak and understand English Exclusion Criteria: - Pregnancy or lactation - Drug addiction defined as any use of cannabis, opioids, or other drugs - Previous or current history of neurological, dermatological, immunological, musculoskeletal, cardiac disorder or mental illnesses (psychiatric diagnosis) that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia etc.) - Moles, wounds, scars, or tattoos in the area to be treated or tested - Current use of medications that may affect the trial such as antihistamines and pain killers. - Participants had known allergy/discomfort to ketamine or amitriptyline - Skin diseases - Consumption of alcohol or painkillers 24 hours before the study days and between these - Acute or chronic pain and itch - Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies) - Lack of ability to cooperate

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketamine 0.5%
Ketamine cream 0.5% will be applied in a 4x4 area in the forearm of each participant.
Amitriptyline
Amitriptyline cream 1% will be applied in a 4x4 area in the forearm of each participant.
ketamine + amitriptyline
A cream containing ketamine 0.5%, amitriptyline 1%, will be applied in a 4x4 area in the forearm of each participant.
Other:
Vehicle
A vehicle cream will be applied in a 4x4 area in the forearm of each participant.
Histamine
After the cream removal, itch will be induced using histamine in the first session
Cowhage
After the cream removal, itch will be induced using cowhage in the second session

Locations

Country Name City State
Denmark Silvia Lo Vecchio Aalborg

Sponsors (1)

Lead Sponsor Collaborator
Aalborg University

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measuring itch by computerized Visual Analog Scale Scoring We will ask the subjects to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable". Immediately after the intervention
Primary Measuring pain by computerized Visual Analog Scale Scoring We will ask the subjects to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable". Immediately after the intervention
Secondary Superficial blood perfusion Superficial blood perfusion (SBP) is measured by a Speckle contrast imager Immediately after the intervention
Secondary Touch Pleasantness Pleasant touch sensation measured using a standardized sensory brush exerting a force of 200 to 400 mN. Immediately after the intervention
Secondary Mechanically evoked itch (MEI), intensity approach MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). Immediately after the intervention
Secondary Mechanically evoked itch, spatial approach The von-Frey filament that better evokes the itch sensation during the assessment of mechanically evoked itch as well as a template of soft plastic are used to map the area of hyperkinesis in the test areas (forearms). Immediately after the intervention
Secondary Mechanical Pain Thresholds (MPT) This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. Immediately after the intervention
Secondary Mechanical Pain Sensitivity (MPS), intensity approach This test is conducted with the same pinprick set used to test the MPT. Immediately after the intervention
Secondary Mechanical Pain Sensitivity (MPS), spatial approach The pinprick that was selected in the MPT as well as a template of soft plastic are used to map the area of hyperalgesia in the test areas (forearms). Immediately after the intervention
Secondary Cold Detection Thresholds (CDT) The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device Immediately after the intervention
Secondary Warm Detection Thresholds (WDT) The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device Immediately after the intervention
Secondary Cold Pain Thresholds (CPT) The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device Immediately after the intervention
Secondary Heat Pain Thresholds (HPT) The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device Immediately after the intervention
Secondary Pain to Supra-threshold Heat Stimuli (STHS) The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device Immediately after the intervention
See also
  Status Clinical Trial Phase
Completed NCT01683552 - Aprepitant in the Management of Biological Therapies-related Severe Pruritus Phase 2
Completed NCT02075632 - Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream Phase 2
Completed NCT04515056 - Characterization of New Human Models of Non-histaminergic Itch N/A
Completed NCT04076865 - Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch N/A
Completed NCT04588532 - Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch N/A
Enrolling by invitation NCT05195177 - Testing Protocol to Efficiently Induce Itch N/A
Withdrawn NCT03943407 - Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch N/A
Completed NCT04858360 - Inhibition of Non-histaminergic Pruritus Applied Using 3 Different Pruritogens N/A
Completed NCT04635254 - The Effect of Halophyte-based Cream on Pain and Itch N/A
Not yet recruiting NCT06201715 - Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis N/A
Completed NCT06036589 - Characterization of Bovine Adrenal Medulla as a Model of Non-histaminergic Itch N/A
Completed NCT04554888 - Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor N/A
Completed NCT04387851 - Learning Mechanisms for Placebo and Nocebo Studies on Somatosensory Sensations: a Systematic Review and Meta-analysis.
Completed NCT03928223 - The Color of Itch; Itch Modification by Color Viewing
Completed NCT03576053 - A Mechanistic Evaluation of the Interactions Between Thermoceptive and Pruriceptive Sensory Processing N/A
Completed NCT04700007 - Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project) N/A
Terminated NCT02828787 - Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging. N/A
Completed NCT04115462 - A Relation of Morphine-induced Itch and Pain Processing N/A
Not yet recruiting NCT04197440 - Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch N/A
Completed NCT05249387 - Characterization of Bovine Adrenal Medulla as a New Surrogate Model of Non-histaminergic Itch N/A